Scholar Rock resubmits Apitegromab BLA to FDA, shares rise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Source: Newsfilter
Scholar Rock Holding Corp's shares surged by 15.30% as the company reached a 20-day high.
The significant price movement follows Scholar Rock's announcement of the resubmission of its Biologics License Application (BLA) for Apitegromab to the FDA, with expectations for acceptance within 30 days and a review period of up to six months. This resubmission includes plans for a second U.S.-based fill-finish facility to enhance the supply chain for Apitegromab, which is aimed at treating spinal muscular atrophy (SMA). The company has also reported positive interactions with the FDA, indicating a strong likelihood of approval.
This development not only boosts Scholar Rock's competitive position in the market but also lays the groundwork for future commercialization of Apitegromab, which could significantly impact SMA patients globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 49.820
Low
42.00
Averages
50.00
High
60.00
Current: 49.820
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock to Present at Goldman Sachs Healthcare Conference
- Conference Announcement: Scholar Rock will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 9, 2026, at 10:00 a.m. ET, highlighting advancements in spinal muscular atrophy (SMA).
- Live Webcast: The event will be available via live webcast on the Scholar Rock website, with a replay accessible for approximately 90 days, ensuring broad dissemination and transparency of information.
- Company Overview: Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab, aimed at improving the lives of patients with SMA and other rare neuromuscular diseases, showcasing its leadership in myostatin biology.
- Innovative Platform: The company leverages its proprietary platform to develop novel monoclonal antibodies that modulate protein growth factors with extraordinary selectivity, aiming to create new treatment possibilities and advance therapies for neuromuscular diseases.
See More
Pharmaceutical Giants' Acquisition Targets Analysis
- Viking Therapeutics Highlights: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, has enrolled over 4,500 patients in Phase 3 ahead of schedule, with oral formulations achieving a 12.2% body weight reduction in 13 weeks, making it a strategically attractive acquisition target with a market cap of $3.69 billion and $706 million in cash.
- Scholar Rock's Market Potential: Scholar Rock's muscle-targeted therapy apitegromab is expected to launch in Europe in H2 2026, already partnered with Novo Nordisk, with a market cap of $5.55 billion and an analyst target price of $57.73, highlighting its significance in the GLP-1 landscape.
- Verve Therapeutics' Outlook: Verve Therapeutics' VERVE-102, a single-dose gene-editing PCSK9 therapy, achieved a 53% mean LDL-C reduction in the Heart-2 Phase 1b trial, with Lilly holding an opt-in that may lead to outright acquisition, showcasing its potential in cardiovascular disease treatment.
- Market Competition Dynamics: Eli Lilly and Novo Nordisk are aggressively acquiring early-stage therapeutics to maintain GLP-1 market dominance, with Lilly's recent four acquisitions indicating its expansion strategy, despite Novo facing pricing pressures and declining sales challenges.
See More
Scholar Rock Grants Equity Awards to New Employees
- Equity Award Overview: Scholar Rock granted inducement equity awards totaling 38,481 shares to six new employees, including 12,061 shares in inducement stock options and 26,420 shares in inducement restricted stock units, reflecting the company's commitment to attracting and retaining talent.
- Option Exercise Price: The inducement stock options have an exercise price of $48.35 per share, matching the closing price of Scholar Rock's common stock on May 11, 2026, indicating the company's confidence in its stock performance over the next three years.
- Vesting Schedule: 25% of the inducement stock options will vest on each employee's first anniversary, with the remaining 75% vesting in 12 quarterly installments, while the restricted stock units will vest in four equal annual installments, ensuring long-term employee retention and contribution.
- Company Background: Scholar Rock focuses on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases, positioning itself as a global leader in myostatin biology and demonstrating its strategic commitment to innovative therapies that create new possibilities for patients.
See More
Scholar Rock Reports Q1 2026 Earnings with Positive FDA Progress
- FDA Application Progress: Scholar Rock's biologics license application (BLA) has been accepted for review by the FDA, with a decision expected by September 30, establishing a solid foundation for market entry in the treatment of spinal muscular atrophy (SMA).
- Production Capacity Assurance: The BLA includes two fill-finish facilities located in Indiana and a second U.S. facility, ensuring that Scholar Rock can rapidly meet market demand upon approval, thereby enhancing its commercial supply capabilities.
- Strong Financial Position: The company ended the first quarter with $480 million in cash and cash equivalents, and secured an additional $100 million from its existing debt facility, demonstrating robust financial support to address the upcoming product launch.
- European Market Outlook: Management indicated that the EMA review of apitegromab is progressing well, with a CHMP opinion anticipated mid-year, which will provide favorable conditions for the company's expansion into the European market, further strengthening its global competitiveness.
See More
Key Wall Street Rating Changes Overview
- LCI Industries Upgrade: Roth upgrades LCI Industries from Hold to Buy with a price target of $164, unchanged, following outsized Q1 EPS, indicating strong profitability that is expected to drive stock price upward.
- VF Corp Upgrade: BTIG raises VF Corp's rating from Neutral to Buy, citing more reasonable estimates reflecting positive outlook for Vans brand, which could enhance market confidence and shareholder returns.
- DaVita's Strong Performance: Deutsche Bank upgrades DaVita from Hold to Buy after reporting Q1 revenues of $3.415 billion, beating consensus by 2.2%, and EPS of $2.87, exceeding expectations by 22.1%, showcasing robust treatment growth and revenue per treatment.
- Monster Beverage Upgrade: Rothschild & Co Redburn upgrades Monster Beverage from Neutral to Buy, highlighting significant international growth potential as the company currently holds only 14% market share, suggesting substantial future market position improvement.
See More
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
Scholar Rock to Present at Goldman Sachs Healthcare Conference
- Conference Announcement: Scholar Rock will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 9, 2026, at 10:00 a.m. ET, highlighting advancements in spinal muscular atrophy (SMA).
- Live Webcast: The event will be available via live webcast on the Scholar Rock website, with a replay accessible for approximately 90 days, ensuring broad dissemination and transparency of information.
- Company Overview: Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab, aimed at improving the lives of patients with SMA and other rare neuromuscular diseases, showcasing its leadership in myostatin biology.
- Innovative Platform: The company leverages its proprietary platform to develop novel monoclonal antibodies that modulate protein growth factors with extraordinary selectivity, aiming to create new treatment possibilities and advance therapies for neuromuscular diseases.
See More
Pharmaceutical Giants' Acquisition Targets Analysis
- Viking Therapeutics Highlights: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, has enrolled over 4,500 patients in Phase 3 ahead of schedule, with oral formulations achieving a 12.2% body weight reduction in 13 weeks, making it a strategically attractive acquisition target with a market cap of $3.69 billion and $706 million in cash.
- Scholar Rock's Market Potential: Scholar Rock's muscle-targeted therapy apitegromab is expected to launch in Europe in H2 2026, already partnered with Novo Nordisk, with a market cap of $5.55 billion and an analyst target price of $57.73, highlighting its significance in the GLP-1 landscape.
- Verve Therapeutics' Outlook: Verve Therapeutics' VERVE-102, a single-dose gene-editing PCSK9 therapy, achieved a 53% mean LDL-C reduction in the Heart-2 Phase 1b trial, with Lilly holding an opt-in that may lead to outright acquisition, showcasing its potential in cardiovascular disease treatment.
- Market Competition Dynamics: Eli Lilly and Novo Nordisk are aggressively acquiring early-stage therapeutics to maintain GLP-1 market dominance, with Lilly's recent four acquisitions indicating its expansion strategy, despite Novo facing pricing pressures and declining sales challenges.
See More
Scholar Rock Grants Equity Awards to New Employees
- Equity Award Overview: Scholar Rock granted inducement equity awards totaling 38,481 shares to six new employees, including 12,061 shares in inducement stock options and 26,420 shares in inducement restricted stock units, reflecting the company's commitment to attracting and retaining talent.
- Option Exercise Price: The inducement stock options have an exercise price of $48.35 per share, matching the closing price of Scholar Rock's common stock on May 11, 2026, indicating the company's confidence in its stock performance over the next three years.
- Vesting Schedule: 25% of the inducement stock options will vest on each employee's first anniversary, with the remaining 75% vesting in 12 quarterly installments, while the restricted stock units will vest in four equal annual installments, ensuring long-term employee retention and contribution.
- Company Background: Scholar Rock focuses on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases, positioning itself as a global leader in myostatin biology and demonstrating its strategic commitment to innovative therapies that create new possibilities for patients.
See More
Scholar Rock Reports Q1 2026 Earnings with Positive FDA Progress
- FDA Application Progress: Scholar Rock's biologics license application (BLA) has been accepted for review by the FDA, with a decision expected by September 30, establishing a solid foundation for market entry in the treatment of spinal muscular atrophy (SMA).
- Production Capacity Assurance: The BLA includes two fill-finish facilities located in Indiana and a second U.S. facility, ensuring that Scholar Rock can rapidly meet market demand upon approval, thereby enhancing its commercial supply capabilities.
- Strong Financial Position: The company ended the first quarter with $480 million in cash and cash equivalents, and secured an additional $100 million from its existing debt facility, demonstrating robust financial support to address the upcoming product launch.
- European Market Outlook: Management indicated that the EMA review of apitegromab is progressing well, with a CHMP opinion anticipated mid-year, which will provide favorable conditions for the company's expansion into the European market, further strengthening its global competitiveness.
See More
Key Wall Street Rating Changes Overview
- LCI Industries Upgrade: Roth upgrades LCI Industries from Hold to Buy with a price target of $164, unchanged, following outsized Q1 EPS, indicating strong profitability that is expected to drive stock price upward.
- VF Corp Upgrade: BTIG raises VF Corp's rating from Neutral to Buy, citing more reasonable estimates reflecting positive outlook for Vans brand, which could enhance market confidence and shareholder returns.
- DaVita's Strong Performance: Deutsche Bank upgrades DaVita from Hold to Buy after reporting Q1 revenues of $3.415 billion, beating consensus by 2.2%, and EPS of $2.87, exceeding expectations by 22.1%, showcasing robust treatment growth and revenue per treatment.
- Monster Beverage Upgrade: Rothschild & Co Redburn upgrades Monster Beverage from Neutral to Buy, highlighting significant international growth potential as the company currently holds only 14% market share, suggesting substantial future market position improvement.
See More
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
